ECOR electroCore, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1560258 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY27.2%
TTM net income YoY-17.5%
TTM EPS YoY-3.8%
Revenue 3-yr CAGR55.1%
Net income 3-yr CAGR—
Margins
Gross margin86.8%
Operating margin-41.1%
Net margin-43.6%
FCF margin-25.8%
EBITDA margin-39.5%
Returns
ROE-478.7%
ROA-71.4%
ROIC (approx.)-1,217.4%
Asset turnover1.64x
Leverage & solvency
Liabilities / assets109.2%
Debt / equity—
Current ratio1.38x
Interest coverage-882.75x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $32.03M | $25.18M |
| Cost of revenue | $4.24M | $3.79M |
| Gross profit | $27.79M | $21.40M |
| R&D expense | — | $2.36M |
| SG&A expense | $38.21M | $31.20M |
| Operating income | -$13.15M | -$12.16M |
| Interest expense | $14,900 | $18,400 |
| Pretax income | -$13.96M | -$11.98M |
| Income tax | $3,000 | -$93,000 |
| Net income | -$13.97M | -$11.89M |
| EBITDA | -$12.65M | -$11.40M |
| EPS (basic) | -1.65 | -1.59 |
| EPS (diluted) | -1.65 | -1.59 |
| Weighted avg. shares (diluted) | 8,483 | 7,483 |
| Balance sheet | ||
| Cash & equivalents | $7.04M | $3.70M |
| Short-term investments | $4.58M | $8.52M |
| Receivables | $1.03M | $1.37M |
| Inventory | $1.63M | $1.68M |
| Current assets | $15.67M | $16.30M |
| PP&E, net | $382,000 | $158,000 |
| Total assets | $18.67M | $20.47M |
| Current liabilities | $11.35M | $9.15M |
| Long-term debt | $6.61M | — |
| Total debt | $6.61M | — |
| Total liabilities | $20.38M | $12.93M |
| Shareholders' equity | -$1.71M | $7.54M |
| Net debt | -$428,000 | — |
| Shares outstanding | 8.00M | 6.65M |
| Cash flow statement | ||
| Operating cash flow | -$8.19M | -$6.95M |
| Capital expenditure | $66,000 | — |
| Free cash flow | -$8.25M | — |
| Investing cash flow | $3.88M | -$8.52M |
| Financing cash flow | $7.63M | $8.44M |
| Depreciation & amortization | $501,000 | $760,000 |
| Stock-based compensation | $1.93M | $1.87M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.